IL-2 Superkine (monomeric):Fc (LALA-PG)-KIH (human) (rec.)

Interleukin-2 (IL-2) is a 133 amino acid glycoprotein with one intramolecular disulfide bond and variable glycosylation. It is secreted by activated T cells and induces proliferation and maturation of activated T cells, natural killer cells and lymphokine activated killer cells. IL-2 also stimulates proliferation of antibody-producing B cells, activates neutrophils and induces mononuclear cells to secrete IFN-γ and TNF-α and -β. Moreover, studies have shown that IL-2 is required for activation-induced apoptosis, an important homeostatic mechanism in the immune system, which is involved in the maintenance of peripheral tolerance to self-antigens.

IL-2 promotes T cell proliferation and particularly naive T cells. IL-2 signaling on activated T cells is effected through a quaternary high-affinity receptor complex consisting of IL-2, IL-2Rα (CD25), IL-2Rβ and IL-2Rγ. Naive T cells are relatively insensitive to IL-2 as they only express small amounts of IL-2Rβ and IL-2Rγ. They only acquire sensitivity after CD25 expression, which captures the cytokine and presents it to the IL-2Rβ and IL-2Rγ receptors. IL-2 Superkine (Fc) is an artificial variant of IL-2 called H9, containing mutations at positions L80F / R81D / L85V / I 86V / I92F. These mutations are located in the molecule's core that acts to stabilize the structure and to give it a receptor-binding conformation mimicking native IL-2 bound to CD25. These mutations effectively eliminate the functional requirement of IL-2 for CD25 expression and elicit proliferation of T cells. Compared to IL-2, the IL-2 superkine induces superior expansion of cytotoxic T cells, leading to improved anti-tumor responses in vivo, and elicits proportionally less toxicity by lowering the expansion of T-regulatory cells and reducing pulmonary oedema.

The protein IL-2 Superkine (monomeric):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IL-2 Superkine:Fc (LALA-PG) Knobs sequence (synthesizing a protein of 45kDa) and one encoding for the Fc Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IL-2 Superkine (monomeric):Fc (LALA-PG)-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcγRs and C1q while FcRn binding and Fc stability remain unaffected.

InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.